Concepedia
Statistics
Publications
33
Citations
7.6K
H-Index
27
Active since
1996
Affiliations
AstraZeneca (United States)(Current)
AstraZeneca (United Kingdom)
Dana-Farber Cancer Institute
National Taiwan University Hospital
The University of Texas MD Anderson Cancer Center
Kenneth S. Thress is an author at AstraZeneca (United States) specializing in medicine, oncology, and molecular oncology.
Publications per year
1996–2021
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
Kenneth S. Thress, Cloud P. Paweletz, Enriqueta Felip et al. · Nature Medicine · 2015 · 1.5K citations · Full text
Medicine, Molecular Biology, Oncology +11
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
Geoffrey R. Oxnard, Kenneth S. Thress, Ryan S. Alden et al. · Journal of Clinical Oncology · 2016 · 843 citations · Full text
Medicine, Oncology, Pharmacology +17
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
Peter Ballard, James Yates, Zhenfan Yang et al. · Clinical Cancer Research · 2016 · 719 citations
Assessment of Resistance Mechanisms and Clinical Implications in Patients With<i>EGFR</i>T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
Geoffrey R. Oxnard, Yuebi Hu, Kathryn F. Mileham et al. · JAMA Oncology · 2018 · 689 citations · Full text
Osimertinib As First-Line Treatment of <i>EGFR</i> Mutation–Positive Advanced Non–Small-Cell Lung Cancer
Suresh S. Ramalingam, James Chih‐Hsin Yang, Chee Khoon Lee et al. · Journal of Clinical Oncology · 2017 · 536 citations
Medicine, Oncology, Pharmacology +14
1–5 of 33